Sawicki Mark W 4

What Happened

• Mark W. Sawicki, Chief Scientific Officer of Cryoport (CYRX), received equity awards on March 14, 2026: 22,845 shares granted and 68,534 derivative awards (total 91,379) at $0.00 per share. On March 16, 2026 he sold 3,235 shares in an open-market/private sale at $8.00 each, netting $25,880. The sale was done to satisfy tax withholding obligations and is routine rather than an investment purchase.

Key Details

• Transaction dates and prices:
  • 2026-03-14 — Award/Grant (A): 22,845 shares @ $0.00 (acquired)
  • 2026-03-14 — Award/Grant (A, derivative): 68,534 units @ $0.00 (contingent/derivative)
  • 2026-03-16 — Sale (S): 3,235 shares @ $8.00 = $25,880 (per footnote, sold to pay taxes)
• Shares owned after transaction: not specified in the summary; see the full Form 4 for total beneficial ownership.
• Footnotes from the filing:
  • F1: These are restricted stock rights — contingent rights to receive one share each that vest in four equal annual installments beginning March 14, 2027.
  • F2: The 3,235-share sale was required by issuer policy to pay taxes due upon vesting (tax withholding).
  • F3: Some awards/options vest 1/48 each month starting April 14, 2026 (monthly vesting schedule).
• Filing timeliness: Form 4 was filed on 2026-03-17 reporting transactions through 2026-03-16. That filing date is within the standard two-business-day window based on the latest reported transaction, so it appears timely.

Context

• The large grants are awards/rights (not cash purchases) and are contingent on vesting schedules; these do not represent an outlay of cash by the insider.
• The small sale was to cover taxes at vesting (tax withholding), a routine administrative transaction that does not necessarily indicate a change in insider sentiment.
• For full details on vesting schedules and total post-transaction holdings, consult the company's filed Form 4 (Accession No. 0001104659-26-029718).